It is reported that elevated expression of LGALS3BP in either serum or tumor tissue is associated with poor clinical outcomes in patients with breast cancer, lung cancer, pancreatic carcinoma, hepatocellular carcinoma, pleural mesothelioma, and neuroblastoma [19]. The gene discussed is LGALS3BP; the disease is breast carcinoma.